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1. Introduction
  Eosinophils (EOS) infiltration is an important pathological 
features of allergic diseases. In recent years, the study 
suggests that it is an important factor in the pathogenesis of 
allergy that EOS migration and activation to the local tissue. 
With the application of molecular biology techniques, the 
chemokine receptor 3 (CCR3) receptors were considered 
to be the EOS selective receptor which with a strong 
inducing chemotaxis effect. The traditional drug therapy 
has a poor specificity and the treatment is ineffective. RNA 
interference has the advantage of specific and targeting 
etc, is regulated by a large number of gene expression of a 
small amount of dsRNA. Currently the reports of the effect 
of inhibiting CCR3 expression on the allergic rhinitis is still 
rare. In this study, we established a mouse model of allergic 
rhinitis and used synthesized interfering RNA in vitro, and 
then observed the changes of mRNA of the EOS CCR3 and 
eosinophil granule proteins-major basic protein (MBP), 
cationic protein (ECP), peroxidase (EPO) expression in mice. 
This stody is to explore the feasibility of the treatment of 
RNA interference (RNAi) for allergic rhinitis. 
2. Materials and methods
2.1. Animals and reagents
  Twenty four male BALB/c mice from 6 to 8 weeks, weight 
20-30 g were purchased from animal and science of 
Objective: To observe the clinical manifestations of allergic rhinitis mice and the expression 
changes of the eosinophils CCR3 and the granule protein mRNA in the bone marrow, peripheral 
blood and nasal lavage fluid. Methods: Twenty-four BALB/c mice were randomly divided into 
the control group, PBS therapy group, siRNA therapy group and the CCR3 siRNA therapy group 
(n=6). Allergic rhinitis model were sensitized and stimulated by ovalbunfin, and CCR3 siRNA 
therapy group were administered with CCR3 transnasally before stimulated. The levels of the 
eosinophils CCR3, MBP, ECP and EPO in bone marrow, peripheral blood and nasal lavage fluid 
were detected by RT-PCR. Results: Compared to the control group and CCR3 siRNA therapy 
group, the nasal mucosa of the PBS therapy group and siRNA therapy group developed epithalaxy, 
goblet cells hyperplasia, squamous epithelium metaplasia, epithelium necrosis, lamina propria 
and submucosa gland hyperplasia, vasodilatation, tissue edema, and the characterized eosinophil 
infiltration. RT-PCR indicated that the CCR3 mRNA, MBP , ECP and EPO expression in bone 
marrow, peripheral blood and nasal lavage fluid of the CCR3 siRNA therapy group was lower than 
the PBS therapy group and siRNA therapy group (P<0.05). Conclusions: The RNA interference 
therapy to CCR3 by local administration pernasal can suppress the process of the development, 
migration and invasion of the allergic rhinitis eosinophil, thus can reduce the effect of eosinophils 
and then reduce the inflammation effect of the allergic rhinitis. It may be a new treatment for 
respiratory tract allergic inflammation. 
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medicine department of Nanchang University. Ovalbumin 
were purchased from Sigma Co., JM109 competent cells, 
a small amount of plasmid extraction kit, Trans2K Plus 
栻 DNA Marker were purchased from Beijing Trans-Gen 
Biotech Co., DNA Primers Synthesis, DNA sequencing were 
purchased from Invitrogen Corporation of USA. Restriction 
endonuclease EcoR 栺, restriction endonuclease Hind 栿, 
restriction endonuclease Mlu 栺, restriction endonuclease 
BamH 栺, restriction endonuclease Xho 栺, T4 DNA Ligase 
were purchased from NEB Inc. Qiagen large-scale plasmid 
extraction kit was purchased from Qiagen, Germany. 
2.2. Construction of CCR3siRNA expression plasmid vector
  CCR3 full-length clone (NM_009914. 4) was used as a 
template to amplify the coding frame sequence. Primer 
was designed and synthesized by BioWit-Technologies. 
shRNA sequences: shRNA1: GGTTGTGTTGATCCTCATAAA 
s h R N A 2 : G C T G A C A A T T G A C A G A T A C C T ; 
shR N A 3 :  G C A G C A T T G C C T G A A T T T A T C ;shR N A 4 : 
GACCACACCCTATGAATATGA. RNAi target sequence was 
designed and the target sequence was synthesized into Oligo 
DNA, annealing for forming the double-stranded DNA, and 
generated shRNA lentiviral vectors with pLVX-shRNA2-m 
vector which were digested by MluI, Sac 栺, EcoR 栺, Hind 
栿, BamH 栺 and Xho 栺. Applied shRNA Lentiviral vector-
transfected 293T cells and EOS cells, determined virus titer. 
Q-PCR identified the downward effect of CCR3 gene in EOS. 
Successfully constructed lentiviral vector plasmid (pLVX-
ShRNA2-mCCR3-1 +2 +3 +4). 
2.3. Animal grouping and sensitized model establishment. 
  In order to avoid the interference caused by external 
allergen, all the animals were kept in the laboratory of 
the department of animal science of medical college of 
Nanchang University, free diet, feeding by circadian rhythm. 
Twenty four clean grade BALB/c mice were randomly 
divided into 4 groups (n=6), one cage for each. Group one 
was the control group given normal saline. Group 2 was 
the PBS group given PBS. Group 3 was the siRNA group, 
given siRNA lentiviral vector. Group 4 was the CCR3 siRNA 
treatment group, given CCR3 siRNA. 8毺L treatment fluid 
were dropped into the nasal cavity on day 0 and day 14, 
respectively, twice a day. The ovalbumin (OVA)/aluminum 
hydroxide [AL (OH)3] mixture [containing 10毺g OVA and 
4 mg AL (OH)3] was injected into the intraperitoneal for 
sensitization on day 2 and day 16, twice a day. 600毺g/mL 
OVA were dropped  intranasal to stimulate allergic reactions 
from day 21 to day 27. The normal control group were 
replaced by the same dose of normal saline. The specimens 
of the mice were collected after 24 h of the administration.
 
2.4. Specimen collection and determination
  Mice were anesthetized by intraperitoneal injection of 5% 
sodium pentobarbital. After anesthesia, the mice were fixed. 
Then 1 mL syringe needle was put into the nasal cavity 
about 2 cm bilateral. 2 mL PBS buffer was used to lavage the 
nasal and recovered the liquid. Pressing the eyeball at the 
mouse inner canthus, tear the retrobulbar tissues and collect 
blood. Exposure the nasal and obtained the bilateral nasal 
mucosa. The mucosa was fixed in 4% paraformaldehyde 
solution, embedded in paraffin, made into 4 毺m sections 
for HE staining. The bone marrow, peripheral blood, nasal 
lavage fluid were stored at -80 ℃ refrigerator, detected by 
CCR3, EPO, MBP and ECP. Performed real-time quantitative 
PCR for the CCR3, EPO, MBP, ECP, and housekeeping gene 
(毬-actin). Reaction conditions: 95 ℃ denaturation 2 min, 
40 cycles, 94 ℃ denaturation 20 s, 49.5 ℃ (CCR3), 55.2 ℃ 
(EPO), 52 ℃ (MBP), 50.9 ℃ (ECP), annealed 20 s, elongation 
at 72 ℃ for 30 s, plate-reading at 74 ℃. PCR products were 
detected by agarose gel electrophoresis. Standardized eNOS, 
ICAM-1, Tenascin-C and PGF2a mRNA absorbance values 
with the internal reference 毬-actin optical density value, 
and obtained the relative content of CCR3, EPO, MBP and 
ECP mRNA expression. 
  The sequence of the CCR3, EPO, MBP and ECP and
毬-actin were as follow: CCR3 upstream primer: 5’CCA GAG 
GGT GAA GAA GAC 3‘, downstream primer: 5’ACC AGG 
AAG AAA CGG AAT 3’. EPO upstream primer: 5’TGG AAA 
GAG GCG TAA TGG 3‘, downstream primer: 5’AAG GAT 
GTA AGT GCG TTG AT 3’. MBP upstream primer: 5’GTT CCC 
AAC ACC AAG ACA 3‘, downstream primer: 5’TCC CAT CCA 
TCC AGC AAA 3’. ECP upstream primer: 5’ATC ACT CAT 
CTG CCA AGC 3‘, downstream primer: 5’CAG GGT TCA CAA 
GGG ACT 3’. 毬-actin primer: 5’GAG ACC TTC AAC ACC 
CCA GC 3‘, downstream primer: 5’ATG TCA CGC ACG ATT 
TCC C 3’. Applicate the transmission ultraviolet analyzer 
for photograph, and then use a laser optical density image 
scanner to scan. The 毬-actin was used as an internal 
reference for semi-quantitative image analysis. 
2.5. Result determination
  Grading: (1) 0: no sneezing, no scratching nose, no 
secretion in nasal cavity; (2) 1 score: times of sneeze <4, 
mild scratching nose, the secretions in anterior nostril; (3) 
2 scores: times of sneeze: 4-10, frequent scratching nose, 
nasal secretions more than anterior nostril; (4) 3 scores: times 
of sneeze> 11, continuous scratching nose, rubbing, face 
covered with nasal secretions. Superimposed quantization 
method was used to record the score. Nasal symptoms of 1-4 
groups were observed after 30 minutes of the stimulation, 
the behavior score was calculated according to this rating 
system  (> 5 is an successful animal model). 
2.6. Statistical analysis
  The data were analyzed by SPSS 19. 0 statistics software, 
and the measurement data were expressed as mean依
SD values. Normal test and homogeneity of variance in 
each group was performed. The data which not normally 
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distributed were converted to normally distributed data by 
natural logarithm. t-test was applied in the comparison 




  The average score of the three groups was greater than 5 
means successful model. The mice in the normal control 
group and CCR3 siRNA group had mild scratching nose and 
less sneezing, total score was <5. That means the allergic 
rhinitis animal model can be successfully established by 
this method, and the application of CCR3 siRNA treatment 
can effectively control the occurrence of allergic rhinitis. 
3.2. Nasal histological changes
  Compared group 1 with group 2 and group 3, the mucosa 
epithelium were shed and the goblet cell hyperplasia was 
obvious and coexsisted with EOS and other inflammatory 
cell infiltration, also with mucosa layer thickening and 
the dilatation and congestion of lamina propria, and tissue 
edema, glandular hyperplasia, hypertrophy strong secretion. 
That is comply with the pathological features of allergic 
rhinitis (Figure 1). 
C                                                                      D
A                                                                      B
Figure 1. HE staining of nasal mucosa. 
A. Group 1: Nasal epithelial cells arranged neatly, no inflammatory 
cell infiltration and no expansion of the gland in the lamina propria 
(HE ×200).
B. Group 2: Nasal lamina propria vascular dilatation and congestion, 
edema, with the infiltration EOS and other inflammatory cell, 
glandular hyperplasia, hypertrophy, strong secretion (HE × 200).
C. Group 3. Nasal epithelium, obviously infiltration of inflammatory 
cells of the goblet cell hyperplasia, thickened mucous layer, tissue 
edema (HE × 200).
D. Group 4: Nasal mucociliary surface layer is relatively complete, no 
thickening of the mucous layer (HE × 200). 
3.3. RT-PCR test results
  In this study, we detected bone marrow, peripheral blood 
and nasal lavage fluid of fresh specimens from 2-4 groups 
of the mice by RT-PCR, and found that after the treatment 
of pLVX-ShRNA2-mCCR3-1 +2 +3 +4 for topical nasal, the 
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Figure 2. CCR3 mRNA expression of bone marrow, blood, nasal 
lavage fluid of mice in each group.
  The relative gray value of CCR3 mRNA of each sample in 
CCR3 siRNA treatment group were as follow: Bone marrow 
(0.340 3依0.022 5), blood (0.253 4依0.061 6), nasal lavage fluid
(0.00依0.00), which  were significantly lower than the relative 
gray value of CCR3 mRNA of each sample in the PBS control 
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Figure 3. Eosinophil MBP mRNA expression of bone marrow, blood, 
nasal lavage fluid of mice in each group.
  The MBP mRNA relative gray value of each sample in the 
CCR3 siRNA group were as follow: Bone marrow (0.324 0依0.024  5),
blood (0.015 3依0.012 8), nasal lavage fluid (0.00依0.00) which 
were significantly lower than the MBP mRNA relative gray 
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Figure 4. ECP mRNA expression of bone marrow, blood, nasal lavage 
fluid of mice in each group. 
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  The ECP mRNA relative gray value of each sample in the 
CCR3 siRNA treatment group were as follow: bone marrow 
(0.493 6依0.011 5), blood (0.140 5依0.026 0), nasal lavage fluid 
(0.00依0.00) which were significantly lower than the ECP 
mRNA relative gray value of the PBS-treated group and the 
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Figure 5. EPO mRNA expression of bone marrow, blood, nasal lavage 
fluid of mice in each group. 
  The EPO mRNA relative gray value of each sample in the 
CCR3 siRNA treatment group were as follow: bone marrow
(0.159 5依0.059 9), blood (0.084 2依0.110 8), nasal lavage fluid 
(0.00依0.00) which were significantly lower than the EPO 
mRNA relative gray-value of the PBS-treated group and the 
siRNA group (P<0.05). 
Table 1
CCR3, MBP, ECP, EPO mRNA relative gray values of the bone 
marrow, the blood and the nasal lavage fluid in three groups (x依sd).
Groups  Bone marrow Blood
Nasa l  l a vage 
fluid
P B S - t r e a t e d 
control group
CCR3 1.115 5依0.048 0 0.670 8依0.026 5 1.048 9依0.013 2
MBP 0.852 9依0.065 0 0.783 7依0.071 2 1.033 1依0.046 9
ECP 0.977 1依0.037 9 0.700 2依0.041 6 0.990 8依0.055 3
EPO 0.485 1依0.054 6 0.697 3依0.133 4 1.050 2依0.041 0
siRNA-treated 
control group
CCR3 1.122 3依0.046 1 0.657 9依0.014 7 1.028 6依0.026 0
MBP 0.914 3依0.036 2 0.697 6依0.068 1 1.086 4依0.053 1
ECP 0.924 5依0.046 7 0.745 6依0.297 1 1.057 6依0.064 7
EPO 0.561 7依0.074 6 0.778 9依0.017 1 0.976 4依0.084 7
CCR3 s iRNA 
treatment group    
CCR3 0.340 3依0.022 5 0.253 4依0.061 6 0.000依0.000
MBP 0.324 0依0.024 5 0.015 3依0.012 8 0.000依0.000
ECP 0.493 6依0.011 5 0.140 5依0.026 0 0.000依0.000
EPO 0.159 5依0.059 9 0.084 2依0.110 8 0.000依0.000
Note: Compared with the PBS-treated control group and the siRNA 
treatment group, P<0.05 (t test), the difference was not statistically 
significant. Compared PBS-treated control group with the siRNA-
treated control group, P>0.05(t test), the difference was not 
statistically significant.
4. Discussion
  Allergic rhinitis belongs to type 栺 allergic reaction, which 
means after atopic individuals exposed to the allergens, 
the IgE-mediated media (mainly histamine) released and 
a variety of immune cells and cytokines involved in the 
nasal mucosa then caused this non-infectious inflammatory 
diseases. A large number of EOS infiltration in tissues is an 
important feature of allergic diseases, and EOS play a role 
of antigen-presenting cells in allergic airway disease[1,2]. 
EOS can release cytotoxic granule proteins, reactive 
oxygen species and lipid mediators, which can cause tissue 
damage, vascular leakage, mucus secretion and airway 
contraction[3]. It has been reported[3-5] that the pathogenesis 
of allergic diseases may be as follows: in the process of 
allergen challenge, the bone marrow can generate specific 
inflammatory cells (EOS progenitor cells), which can reach to 
the local tissue by peripheral blood circulation and then led 
to the local inflammation. 
  CCR3 is a G protein coupled receptor generated by 
transmembrane, primarily expressed in the EOS. Eosinophil 
activation chemokine (Eotaxin) belong to class CC 
chemokines, which combined with the CCR3 and induce 
eosinophil migrate to specific tissues, causing local tissue 
inflammation. Eotaxins can also play an important role in 
situ hematopoiesis of the EOS in sites of inflammation by 
CCR3 receptors[4-9]. RNAi is a mechanism which can make 
target gene silencing after specific transcription, dsRNA can 
cause the degradation of the homologous mRNA and lead to 
the undetectable expression of target gene. It can blocking 
the specific gene expression efficiently. Therefore, the use 
of RNAi technology for screening genome have been studied 
extensively. That is, design corresponding dsRNA for the 
different part of the genome, construct dsRNA libraries, 
introduced into different individual cells, the protein 
expression can be changed to filter the gene and determine 
gene function[11-15]. Therefore, our experiments adopted the 
external synthesized interference RNA, specifically inhibit 
the eosinophil CCR3 expression, observed the EOS CR3 and 
eosinophil granule proteins-MBP, ECP, EPO mRNA changes 
in mice bone marrow, peripheral blood and nasal lavage 
fluid EOS. 
  In our previous work, we first estabalish the animals 
model, calculated by behavioral scoring system(>5 is a 
successful animal model), we found that the average score 
of group 2 and group 3 were all> 5. The normal group and 
CCR3 siRNA group only with mild scratching nose and less 
sneezing, score<5. HE staining showed that compared with 
group 1, group 2 and group 3 were with significantly mucosal 
epithelium, goblet cell hyperplasia and EOS and other 
inflammatory cells, mucous layer thickening, dilatation 
and congestion of the lamina propria, tissue edema, gland 
hyperplasia and great hypertrophy secretion. That means 
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the allergic rhinitis animal model can be successfully 
established by this method, and the application of CCR3 
siRNA treatment can effectively control the occurrence of 
allergic rhinitis. 
  Our previous studies has applied lentiviral vectors to 
constructed simultaneously for four fragments (mCCR3-1, 
mCCR3-2, mCCR3-3 and mCCR3-4) CCR3 siRNA 
expression shuttle plasmid (pLVX-ShRNA2-mCCR3-1 +2 + 
3 +4) successfully, and have a higher silencing effect which 
identified by QPCR on EOS CCR3 gene[16]. Detected by RT-
PCR it was found that EOS CCR3 mRNA granule protein 
mRNA expression were high in the bone marrow, peripheral 
blood and nasal lavage fluid of the allergic rhinitis mice, 
which indicating that the EOS involved in the localization 
and activation of the tissue during the disease pathogenesis. 
In the experimental group, after treatmen of topical nasal 
pLVX-ShRNA2-mCCR3-1 +2 +3 +4, the test results show the 
corresponding EOS CCR3 mRNA and granule protein mRNA 
(MBP, ECP, EPO) expression was decreased, and reducing 
the changes of nasal cavity mucosa pathological, which 
indicate that the application-specific CCR3 siRNA can 
inhibite CCR3 expression and also decreased the eosinophil 
granule protein mRNA expression. This shows that the CCR3 
may be involved in the whole process of the development, 
migration and invasion of EOS, which can not only block 
the CCR3 receptor expression, but also block its maturation, 
activation and chemotaxis, and blocking the recruitment of 
hematopoietic progenitor cells, mature eosinophil to sites of 
inflammation, improve the inflammatory response of allergic 
rhinitis[6,17,18]. 
  In this study, we investigated the use of RNAi technology 
to treat allergic rhinitis of mice model, we found that 
inhibit the expression of CCR3 mRNA can reduce the 
eosinophil granule protein mRNA expression in the the bone 
marrow, peripheral blood and nasal lavage fluid, improved 
pathological changes in the nasal mucosa of mice, which 
indicated that EOS is suppressed in the development, 
migration and invasion , so as to relieve nasal allergy of the 
allergic rhinitis. Thus, based on the efficient and specific 
sequence interference for the target gene CCR3, we can 
provide some ideas for future exploration of the targeting 
siRNA gene therapy for allergic rhinitis. 
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